Silver Book Fact

Drugs like bevacizumab- designed to impede the growth of blood vessels and tumors- can cost more than $100,000 per patient. 

Ubel P, Berry S, Nadler E, Bell C, et al. In a Survey, Marked Inconsistency in How Oncologists Judged Value of High-Cost Cancer Drugs in Relation to Gains in Survival. Health Aff. 2012; 31(4): 709-717. http://content.healthaffairs.org/content/31/4/709.abstract

Reference

Title
In a Survey, Marked Inconsistency in How Oncologists Judged Value of High-Cost Cancer Drugs in Relation to Gains in Survival
Publication
Health Aff
Publisher
Project HOPE
Publication Date
2012
Authors
Ubel P, Berry S, Nadler E, Bell C, et al
Volume & Issue
Volume 31, Issue 4
Pages
709-717
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • In 1971, one in 69 people was a cancer survivor (three million survivors). In 2014, that number grew to one in 22 people (14.5 million survivors).  
  • Improvements in surgical techniques and combination therapies increased the 1-year survival rate for lung cancer from 34 percent in 1975-1977 to 45 percent in 2006-2009.  
  • Use of tamoxifen, a drug used to treat breast cancer, has resulted in a direct cost savings of $41,372 per year of life gained in women 35- to 49-years-old, $68,349…  
  • Since Congress passed the National Cancer Act in 1971, the percentage of the U.S. population living with, through, or beyond a cancer diagnosis has more than tripled.  
  • Thousands of potential cancer medicines in development